Compare · LLY vs RAPP
LLY vs RAPP
Side-by-side comparison of Eli Lilly and Company (LLY) and Rapport Therapeutics Inc. (RAPP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and RAPP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 544.8x RAPP ($2.04B).
- Over the past year, LLY is up 52.7% and RAPP is up 189.5% - RAPP leads by 136.7 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 6 for RAPP).
- LLY has more recent analyst coverage (25 ratings vs 11 for RAPP).
- Company
- Eli Lilly and Company
- Rapport Therapeutics Inc.
- Price
- $1178.57+0.73%
- $42.53+5.86%
- Market cap
- $1.11T
- $2.04B
- 1M return
- +5.00%
- +10.67%
- 1Y return
- +52.71%
- +189.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 11
- 6
- Recent ratings
- 25
- 11
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
Latest RAPP
- Chief Executive Officer Ceesay Abraham sold $328,437 worth of shares (8,210 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 539,817 units (SEC Form 4)
- Chief Operating Officer Gault Cheryl sold $415,798 worth of shares (10,000 units at $41.58) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 149,914 units (SEC Form 4)
- Chief Executive Officer Ceesay Abraham sold $327,398 worth of shares (8,220 units at $39.83) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 548,027 units (SEC Form 4)
- SEC Form 144 filed by Rapport Therapeutics Inc.
- SEC Form 144 filed by Rapport Therapeutics Inc.
- Leerink Partners initiated coverage on Rapport Therapeutics with a new price target
- SEC Form 4 filed by Director Maraganore John
- SEC Form 4 filed by Director Perez Robert J
- SEC Form 4 filed by Director Paul Steven M
- SEC Form 4 filed by Director Silva Paul M